In this issue:
Novel risk stratification algorithm for relapsed MM
Daratumumab + standard care in newly diagnosed MM
Response-adapted cyclophosphamide/bortezomib/dexamethasone intensification in newly diagnosed MM
Lenalidomide dose, duration and immunomodulator-free interval in pomalidomide/dexamethasone-treated MM
Allogeneic SCT in MM
OS with D-VMP in newly diagnosed MM
Enriching circulating myeloma cells by flow cytometry + IMBs
Peripheral neuropathy following bortezomib in MM
Treating elderly SCTineligible MM using CyBorD ±thalidomide-based consolidation
Outpatient autologous SCT for MM
Please login below to download this issue (PDF)